Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 6/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 6/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.36 |
| ▸ | THRA | P10827 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121100 | 0.92 | GRIN2B (0.36) | KCNQ3KCNQ2SLC9A1FFAR1 | |
| SCHEMBL23888027 | 0.92 | GRIN2B (0.36) | KCNQ3KCNQ2SLC9A1FFAR1 | |
| SCHEMBL23895796 | 0.89 | GRIN2B (0.34) | KCNQ3KCNQ2FFAR1 | |
| SCHEMBL23895798 | 0.86 | SLC9A1 (0.35) | KCNQ3KCNQ2GRM5SLC9A1SLC9A2 | |
| SCHEMBL23895791 | 0.86 | PTGDR2 (0.45) | PTGDR2PTGDRFFAR1PPARD | |
| SCHEMBL30121049 | 0.85 | PPARD (0.37) | THRATHRBFFAR1PTGER2PPARD | |
| SCHEMBL23887694 | 0.85 | PPARD (0.37) | THRATHRBFFAR1PTGER2PPARD | |
| SCHEMBL23896086 | 0.83 | FFAR1 (0.38) | GRM5FFAR1PTGER2PPARD | |
| SCHEMBL23887753 | 0.81 | FFAR1 (0.36) | THRATHRBFFAR1PTGER2PPARD | |
| SCHEMBL23896089 | 0.79 | GRM5 (0.34) | GRM5SLC9A1SLC9A2PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | PTGDR2 2867/4885PTGDR 2647/4885KCNQ3 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.